Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Optimisation des stratégies de rétention, de durée et d'arrêt pour la pharmacothérapie des troubles liés à l'utilisation d'opioïdes (RDD)

9 novembre 2026 mis à jour par: NYU Langone Health

NIDA-CTN-0100 : Optimisation des stratégies de rétention, de durée et d'arrêt de la pharmacothérapie des troubles liés à l'utilisation d'opioïdes (RDD)

This is a two phase study investigating combinations of pharmacological and behavioral interventions to optimize the treatment of Opioid Use Disorder (OUD). The Retention Phase will assess strategies for improving retention on buprenorphine (BUP) and extended-release injectable naltrexone (XR-NTX). The Discontinuation Phase will assess which approaches are most likely to lead to long-term success (absence of relapse), and what characteristics of participants distinguish those who can safely discontinue Medications for Opioid Use Disorder (MOUD) from those who remain at risk of relapse and should not discontinue.

Aperçu de l'étude

Statut

Actif, ne recrute pas

Les conditions

Intervention / Traitement

Description détaillée

The main objectives of this study are:

  1. To test strategies to improve retention in treatment on medications for opioid use disorder (MOUD), among patients initiating treatment for OUD.
  2. To test strategies to improve outcomes among patients who have achieved stable remission on MOUD and want to discontinue MOUD.
  3. To develop models to predict who is able to discontinue MOUD without relapse, based on patient characteristics, including duration of MOUD prior to discontinuation.

The study will have a multicenter, randomized, pragmatic non-blinded design. The study has two phases, a Retention Phase and a Discontinuation Phase.

Type d'étude

Interventionnel

Inscription (Réel)

1516

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Arkansas
      • Little Rock, Arkansas, États-Unis, 72205
        • University of Arkansas for Medical Sciences (UAMS) / Center for Addiction Services and Treatment (CAST)
    • California
      • Tarzana, California, États-Unis, 91356
        • Tarzana Treatment Centers, Inc.
    • Connecticut
      • Bridgeport, Connecticut, États-Unis, 06610
        • Liberation Programs, Inc.
    • Florida
      • Clearwater, Florida, États-Unis, 33760
        • Operation PAR
      • Jacksonville, Florida, États-Unis, 32204
        • Gateway Community Services
      • Orlando, Florida, États-Unis, 32806
        • Aspire Health Partners
    • Maryland
      • Baltimore, Maryland, États-Unis, 21229
        • Mountain Manor / Maryland Treatment Centers
    • Massachusetts
      • Belmont, Massachusetts, États-Unis, 02478
        • McLean Hospital
      • Fall River, Massachusetts, États-Unis, 02720
        • Stanley Street Treatment and Resources, Inc.
      • Newton, Massachusetts, États-Unis, 02458
        • Square Medical Group, LLC
    • Missouri
      • Cape Girardeau, Missouri, États-Unis, 63703
        • Gibson Center for Behavioral Change
    • New Hampshire
      • Lebanon, New Hampshire, États-Unis, 03766
        • Dartmouth Hitchcock - ATP
    • New Mexico
      • Albuquerque, New Mexico, États-Unis, 87106
        • University of New Mexico Addiction and Substance Abuse Program
    • New York
      • New York, New York, États-Unis, 10016
        • Bellevue Hospital Center
    • Oregon
      • Roseburg, Oregon, États-Unis, 97470
        • Adapt Integrated Health Care
      • Winston, Oregon, États-Unis, 97496
        • Adapt Integrated Health Care
    • Pennsylvania
      • Pittsburgh, Pennsylvania, États-Unis, 15213
        • Center for Psychiatric and Chemical Dependency Services (CPCDS)
      • Pittsburgh, Pennsylvania, États-Unis, 15219
        • Internal Medicine Recovery Engagement Program (IM-REP)
    • South Carolina
      • Conway, South Carolina, États-Unis, 29526
        • Shoreline Behavioral Health Services
    • Utah
      • Salt Lake City, Utah, États-Unis, 84108
        • Huntsman Mental Health Institute / University of Utah
    • West Virginia
      • Morgantown, West Virginia, États-Unis, 26505
        • Chestnut Ridge Center

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria for Retention Phase:

  1. 18 years of age or older;
  2. Meet DSM-5 criteria for current opioid use disorder (heroin, fentanyl or other synthetic opioids, and/or prescription opioids);
  3. Seeking treatment for opioid use disorder and choosing either buprenorphine (BUP) or extended-release injection naltrexone (XR-NTX);
  4. If choosing buprenorphine, willing to be randomized to SL-BUP-16mg, SL-BUP-32mg, or XR-BUP;
  5. Willing to be randomized to either MM (standard Medical Management plus counseling treatment as usual available at the site) or MMR (MM plus usual counseling and access to an app delivering CM + CBT);
  6. In good-enough general health (meaning good enough health to be in outpatient treatment) as determined by the study medical clinician on the basis of medical history, review of systems, and physical/mental status exam, to permit treatment with XR-NTX or BUP;
  7. Willing and able to provide written informed consent;
  8. Able to speak English sufficiently to understand the study procedures;
  9. If female of childbearing potential, willing to practice an effective method of birth control for the duration of participation in the study (participants who become pregnant during the study will continue to be followed; treatment may be modified consistent with pregnancy).

Exclusion Criteria for Retention Phase:

  1. Serious medical, psychiatric, or co-occurring substance use disorder or concomitant medication that, in the opinion of the study medical clinician, makes the patient not appropriate for outpatient treatment with buprenorphine or XR-NTX, but instead requires a higher or different level of care. Examples include:

    1. Disabling or terminal medical illness (e.g., uncompensated heart failure, cirrhosis or end-stage liver disease) as assessed by medical history, review of systems, physical exam and/or laboratory assessments;
    2. Severe, untreated or inadequately treated psychiatric condition (e.g., active psychosis, uncontrolled bipolar disorder) as assessed by history and/or clinical interview, requiring a different level of care (e.g., hospitalization);
    3. Current severe alcohol, benzodiazepine, or other depressant or sedative hypnotic use, requiring a different level of care (e.g., hospitalization);
  2. Suicidal or homicidal ideation or behavior requiring a different level of care (e.g., hospitalization);

  3. Known allergy or sensitivity to preferred medication or its components;

  4. Maintenance on methadone at the time of signing consent;

  5. For those preferring XR-NTX, presence of pain of sufficient severity as to require ongoing pain management with opioids;

  6. For those preferring XR-NTX, body habitus that, in the judgment of the study physician, precludes safe intramuscular injection of XR-NTX (e.g., BMI>40, excess fat tissue over the buttocks, emaciation);

  7. If female, currently pregnant or breastfeeding or planning on conception;

  8. Are currently in jail, prison or other overnight facility as required by court of law or have pending legal action that could prevent participation in study activities;

  9. Have used the reSET-O or CHESS Connections mHealth apps in the 3 months prior to consent;

  10. Other major reasons that might prevent an individual from participating in the study (e.g., a planned move out of the area).

Inclusion Criteria for Discontinuation Phase:

  1. 18 years of age or older;
  2. Have been receiving buprenorphine for OUD for at least the past year or XR-NTX pharmacotherapy for OUD for at least the past 6 months prior to consent for the Discontinuation Phase;
  3. Express the desire to discontinue MOUD after a shared decision-making discussion with the treating provider;
  4. Meet stability criteria, i.e., have abstained from opioids (other than buprenorphine), cocaine, methamphetamine, and non-prescribed benzodiazepines for the past ≥12 weeks, and do not meet DSM-5 criteria for current (≥12 weeks) alcohol use disorder (participants with cannabis use will be eligible);
  5. If currently taking buprenorphine, are willing to take either SL-BUP or XR-BUP if randomized to that condition;
  6. Willing to be randomized to either MM or to MMD;
  7. Able to provide written informed consent after discussion with their provider regarding the risks of discontinuation;
  8. Able to speak English sufficiently to understand the study procedures;
  9. If female of childbearing potential, willing to practice an effective method of birth control while in the study and taking study medication (participants who become pregnant during the study will continue to be followed; treatment may be modified consistent with pregnancy).

Exclusion Criteria for Discontinuation Phase:

  1. Serious medical or psychiatric disorder or concomitant medication that, in the opinion of the study medical clinician, would make study participation hazardous to the participant or compromise study findings or would prevent the participant from completing the study. Examples include:

    1. Disabling or terminal medical illness (e.g., uncompensated heart failure, cirrhosis or end-stage liver disease) as assessed by medical history, review of systems, physical exam and/or laboratory assessments;
    2. Severe, untreated, or inadequately treated psychiatric condition (e.g., active psychosis, uncontrolled bipolar disorder) as assessed by history and/or clinical interview, requiring a different level of care (e.g., hospitalization);
  2. Suicidal or homicidal ideation or behavior requiring a different level of care (e.g., hospitalization);

  3. For participants entering the study taking buprenorphine, presence of pain requiring or likely requiring ongoing pain management with buprenorphine or other opioids;

  4. If female, currently pregnant or breastfeeding or planning on conception;

  5. Use of opioids (other than buprenorphine), cocaine, methamphetamine, or non-prescribed benzodiazepines in the past 12 weeks;

  6. Meets current DSM-5 criteria for any current alcohol use disorder;

  7. Are currently in jail, prison or other overnight facility as required by court of law or have pending legal action that could prevent participation in study activities;

  8. Have used the Connections mHealth app in the 3 months prior to consent (other than Connections in the Retention Phase);

  9. Other major reasons that might prevent an individual from participating in the study (e.g., a planned move out of the area.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation factorielle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Retention: SL-BUP standard dose + MM

Standard dose sublingual buprenorphine-naloxone (SL-BUP) 16mg/day target plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

Daily dosing of sublingual buprenorphine-naloxone

Autres noms:
  • Suboxone
  • buprénorphine sublinguale

MM consists of standard Medical Management and the usual counseling at the treatment program.

Expérimental: Retention: SL-BUP high dose + MM

High dose sublingual buprenorphine-naloxone (SL-BUP) 32mg/day target plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

Daily dosing of sublingual buprenorphine-naloxone

Autres noms:
  • Suboxone
  • buprénorphine sublinguale

MM consists of standard Medical Management and the usual counseling at the treatment program.

Expérimental: Retention: XR-BUP + MM

Extended-release injectable buprenorphine (XR-BUP) plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

MM consists of standard Medical Management and the usual counseling at the treatment program.

Weekly/monthly dosing of extended-release injectable buprenorphine

Autres noms:
  • CAM2038
  • buprénorphine à libération prolongée
  • Brixadi
Expérimental: Retention: XR-NTX + MM

Extended-release injectable naltrexone (XR-NTX) plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

MM consists of standard Medical Management and the usual counseling at the treatment program.

Monthly dosing of extended-release injectable naltrexone

Autres noms:
  • Vivitrol
  • naltrexone à libération prolongée
Expérimental: Retention: SL-BUP standard dose + MMR

Standard dose sublingual buprenorphine-naloxone (SL-BUP) 16mg/day target plus MMR, consisting of Medical Management and usual counseling, plus a technology-based behavioral component.

Daily dosing of sublingual buprenorphine-naloxone

Autres noms:
  • Suboxone
  • buprénorphine sublinguale

MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Expérimental: Retention: SL-BUP high dose + MMR

High dose sublingual buprenorphine-naloxone (SL-BUP) 32mg/day target plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Daily dosing of sublingual buprenorphine-naloxone

Autres noms:
  • Suboxone
  • buprénorphine sublinguale

MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Expérimental: Retention: XR-BUP + MMR

Extended-release injectable buprenorphine (XR-BUP) plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Weekly/monthly dosing of extended-release injectable buprenorphine

Autres noms:
  • CAM2038
  • buprénorphine à libération prolongée
  • Brixadi

MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Expérimental: Retention: XR-NTX + MMR

Extended-release injectable naltrexone (XR-NTX) plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Monthly dosing of extended-release injectable naltrexone

Autres noms:
  • Vivitrol
  • naltrexone à libération prolongée

MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Expérimental: Discontinuation: Discontinue SL-BUP with SL-BUP + MM

Start on SL-BUP, taper with SL-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

Daily dosing of sublingual buprenorphine-naloxone

Autres noms:
  • Suboxone
  • buprénorphine sublinguale

MM consists of standard Medical Management and the usual counseling at the treatment program.

Expérimental: Discontinuation: Discontinue SL-BUP with XR-BUP + MM

Start on SL-BUP, taper with XR-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

MM consists of standard Medical Management and the usual counseling at the treatment program.

Weekly/monthly dosing of extended-release injectable buprenorphine

Autres noms:
  • CAM2038
  • buprénorphine à libération prolongée
  • Brixadi
Expérimental: Discontinuation: Discontinue XR-BUP with XR-BUP + MM

Start on XR-BUP, taper with XR-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

MM consists of standard Medical Management and the usual counseling at the treatment program.

Weekly/monthly dosing of extended-release injectable buprenorphine

Autres noms:
  • CAM2038
  • buprénorphine à libération prolongée
  • Brixadi
Expérimental: Discontinuation: Discontinue XR-NTX with XR-NTX + MM

Start on XR-NTX, taper with XR-NTX, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

MM consists of standard Medical Management and the usual counseling at the treatment program.

Monthly dosing of extended-release injectable naltrexone

Autres noms:
  • Vivitrol
  • naltrexone à libération prolongée
Expérimental: Discontinuation: Discontinue SL-BUP with SL-BUP + MMD

Start on SL-BUP, taper with SL-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Daily dosing of sublingual buprenorphine-naloxone

Autres noms:
  • Suboxone
  • buprénorphine sublinguale

MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Expérimental: Discontinuation: Discontinue SL-BUP with XR-BUP + MMD

Start on SL-BUP, taper with XR-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Weekly/monthly dosing of extended-release injectable buprenorphine

Autres noms:
  • CAM2038
  • buprénorphine à libération prolongée
  • Brixadi

MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Expérimental: Discontinuation: Discontinue XR-BUP with XR-BUP + MMD

Start on XR-BUP, taper with XR-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Weekly/monthly dosing of extended-release injectable buprenorphine

Autres noms:
  • CAM2038
  • buprénorphine à libération prolongée
  • Brixadi

MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Expérimental: Discontinuation: Discontinue XR-NTX with XR-NTX + MMD

Start on XR-NTX, taper with XR-NTX, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Monthly dosing of extended-release injectable naltrexone

Autres noms:
  • Vivitrol
  • naltrexone à libération prolongée

MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Retention: Continuous retention in MOUD treatment through 26 weeks
Délai: Retention: from randomization through week 26

Binary (yes/no). Continuously enrolled in maintenance treatment on one or more of the evidence-based MOUD modalities (e.g., SL-BUP, XR-BUP, XR-NTX, or methadone maintenance) with no more than a 28-day gap on MOUD over the 26-week period.

Retention: from randomization through week 26
Discontinuation: Completed Discontinuation without Relapse
Délai: Discontinuation: from randomization through week 24 follow up

Binary (yes/no). Discontinuing MOUD during the taper period, no return to MOUD, and no relapse to opioid use, either during the taper (up to 48 weeks for those entering on BUP or 24 weeks for those entering on XR-NTX) or during the 24 weeks after MOUD is discontinued.

Discontinuation: from randomization through week 24 follow up

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Retention KS1: Weekly opioid abstinence
Délai: Retention: from randomization through week 26

Weekly opioid abstinence (measured by Timeline Followback, not contradicted by toxicology test). Repeated yes/no measure for each of weeks 1 through 26.

Retention: from randomization through week 26
Retention KS2: Treatment effectiveness
Délai: Retention: at week 26

Retention treatment effectiveness, measured by the Treatment Effectiveness Assessment (TEA, Ling et. al, 2012); a brief instrument to assess patient progress in treatment and recovery along 4 domains (substance use, health, lifestyle and community) at week 26.

Retention: at week 26
Retention KS3: Treatment by baseline severity
Délai: Retention: at week 26

Treatment by baseline severity interaction where severity is indicated by the randomization stratum injection use (yes/no).

Retention: at week 26
Discontinuation KS1: Completed Discontinuation
Délai: Discontinuation: from randomization through week 24 follow up

Completed Discontinuation without regard to relapse status

Discontinuation: from randomization through week 24 follow up
Discontinuation KS2: Relapse
Délai: Discontinuation: from randomization through week 24 follow up

Relapse - separate binary outcome without regard to discontinuation status

Discontinuation: from randomization through week 24 follow up
Discontinuation KS3: Safety
Délai: Discontinuation: from randomization through week 24 follow up

Safety outcomes (binary, any one or more occurrences): overdoses, all non-fatal plus fatal.

Discontinuation: from randomization through week 24 follow up
Discontinuation KS4: Treatment effectiveness
Délai: Discontinuation: at end of taper (EoT) and week 24 follow up

Discontinuation treatment effectiveness, measured by the Treatment Effectiveness Assessment (TEA, Ling et. al, 2012); a brief instrument to assess patient progress in treatment and recovery along 4 domains (substance use, health, lifestyle and community) at week 24. Measured at the end of taper (EOT): up to 24 weeks for tapers with XR-NTX and up to 48 weeks for tapers with BUP; and at the week 24 follow up (primary outcome timepoint).

Discontinuation: at end of taper (EoT) and week 24 follow up

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Collaborateurs

Les enquêteurs

  • Chercheur principal: Edward V Nunes, MD, New York State Psychiatric Institute/Columbia University Irving Medical Center
  • Chercheur principal: Roger Weiss, MD, Harvard Medical School/McLean Hospital
  • Chercheur principal: John Rotrosen, MD, NYU Langone Health

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

8 juin 2021

Achèvement primaire (Estimé)

31 décembre 2026

Achèvement de l'étude (Estimé)

31 janvier 2027

Dates d'inscription aux études

Première soumission

29 juin 2020

Première soumission répondant aux critères de contrôle qualité

6 juillet 2020

Première publication (Réel)

9 juillet 2020

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

10 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

9 novembre 2026

Dernière vérification

1 juillet 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 19-01363
  • UG1DA015831 (Subvention/contrat des NIH des États-Unis)
  • CTN-0100 (Autre identifiant: NIDA Clinical Trials Network)
  • UG1DA013035 (Subvention/contrat des NIH des États-Unis)
  • 20-PRS-057 (Autre identifiant: Biomedical Research Alliance of New York (BRANY) sIRB)
  • 146193 (Autre identifiant: FDA/IND#)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

This study will comply with the NIH Data Sharing Policy and Implementation Guidance (https://grants.nih.gov/grants/policy/data_sharing/data_sharing_guidance.htm) and (for HEAL-funded studies) the HEAL Public Access and Data Sharing Policy (https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative/research/heal-public-access-data-sharing-policy).

Primary data for this study will be available to the public in the NIDA data repository. For more details on data sharing please visit https://datashare.nida.nih.gov/.

The primary outcome(s) publication will be included along with study underlying primary data in the data share repository, and it will also be deposited in PubMed Central http://www.pubmedcentral.nih.gov/ per NIH Policy (http://publicaccess.nih.gov/).

Délai de partage IPD

Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .